Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...

Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...

Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing ...

Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...

Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast cancers. A recently completed phase 3 clinical trial, conducted by ...

There is no cure for PIK3CA-related overgrowth spectrum, but several options are available to treat the root cause of the condition and help manage symptoms. These include targeted therapy, medication ...